JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2023. Vol. 68. № 3
DOI: 10.33266/1024-6177-2023-68-3-57-65
A.S. Krylov1, B.Ya. Narkevich1, 2, A.D. Ryzhkov1, 3, V.V. Krylov4, T.M. Geliashvili1, A.I. Pronin1
The Efficacy of Radionuclide Therapy for Bone Metastasis
1 N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia
2Association of Medical Physicists of Russia, Moscow, Russia
3Russian Medical Academy of Continuous Professional Education, Moscow, Russia
4A.F. Tsyb Medical Radiology Research Center, Obninsk, Russia
Contact persons: Boris Yaroslavovich Narkevich, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: Development of a methodology for evaluating the effectiveness of radionuclide therapy for bone metastases based on dosimetric and clinical and laboratory criteria.
Material and methods: A comparative analysis of the functionality of various criteria for assessing the long-term and short-term effectiveness of radionuclide therapy of bone metastases was carried out. Focal absorbed doses of internal exposure are considered as one of the criteria, for the determination of which a simplified method for their calculation is proposed based on quantitative data from SPECT/CT scanning of an X-ray phantom and a real patient who has been injected with a β-γ-emitting therapeutic radiopharmaceutical.
Results: On a clinical example of radionuclide therapy with 177Lu-PSMA-617 in a patient with stage 4 prostate cancer, dose estimates of internal irradiation of foci with β-particles were obtained. Calculations were made for bone metastases of 7 localizations in dynamics for each of the 5 fractions of the course of radionuclide therapy. It is shown that the total focal doses for 5 fractions of internal exposure vary from 70.6 to 116.8 Gy for different foci, which corresponds to the literature data obtained by more accurate methods of dosimetry of internal exposure. The obtained dosimetric data were compared with efficacy estimates based on metabolic, hematological, hormonal and biochemical parameters, as well as on the tumor marker PSA.
Conclusion: The main criterion for assessing the antitumor efficacy of radionuclide therapy is the metabolic activity of bone foci, while data on the accumulated focal doses of internal β-irradiation are of an auxiliary nature. Hematological indicators should be the criteria for assessing radiotoxicity and used to adjust the course of radionuclide therapy.
Keywords: radionuclide therapy, β-γ-emitting radiopharmaceuticals, bone metastases, internal irradiation, therapy effectiveness, evaluation criteria, dosimetric parameters, clinical and laboratory parameters
For citation: Krylov AS, Narkevich BYa, Ryzhkov AD, Krylov VV, Geliashvili TM, Pronin AI. The Efficacy of Radionuclide Therapy for Bone Metastasis. Medical Radiology and Radiation Safety. 2023;68(3):57–65. (In Russian). DOI: 10.33266/1024-6177-2023-68-3-57-65
References
- ICRU Report 96. Dosimetry-Guided Radiopharmaceutical Therapy. Journal of ICRU. 2021; 21(1).
- Росcийские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Под рук. И.В. Поддубной, В.Г. Савченко М.: ММА МедиаМедика, 2014. [Russian clinical guidelines for the diagnosis and treatment of lymphoproliferative diseases. Poddubnaya IV, Savchenko VG. M.: MMA MediaMedica, 2014. (In Russian)].
- Гележе П. В., Морозов С. П., Мандельблат Ю. Э., Либсон Е. И. Что нового в критериях оценки онкологических заболеваний в лучевой диагностике: RECIST vs. PERCIST. Лучевая диагностика и терапия. 2014. № 2(5). С. 28–36. [Gelezhe PV, Morozov SP, Mandelblat YuE, Libson EI. Whatʼs News in Cancer Evaluation Criteria in Medical Imaging: RECIST vs. PERCIST. Radiation Diagnostics and Therapy. 2014; (2(5)):28-36. (In Russian)].
- Bentzen SM, Constine LS, Deasy JO, et al. Quantitative analyses of normal tissue effects in the clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 2010; 76(3): 3–9.
- Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nature Reviews: Drug Discovery. 2020; 19: 589-608.
- Наркевич Б.Я., Крылов А.С., Рыжков А.Д. Упрощенный способ расчета доз внутреннего облучения костных метастазов при радионуклидной терапии. Медицинская физика. 2023. № 1(97). С. 43-56. [Narkevich BYa, Krylov AS, Ryzhkov AD. A simplified method for calculating internal doses of bone metastases during radionuclide therapy. Medical Physics. 2023;(1(97)):43-56. (In Russian)].
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.01.2022. Accepted for publication: 25.02.2023.